Related Experiment Video
Updated: May 21, 2026

Neonatal Cardiac Scaffolds: Novel Matrices for Regenerative Studies
Published on: November 5, 2016
Regenerative therapies in neonatology: clinical perspectives
L Gortner1, U Felderhoff-Müser, D Monz
1Pediatric Hospital, University of the Saarland, Homburg, Germany. ludwig.gortner@uks.eu
Insights
Stem cell therapy shows promise for treating severe neonatal diseases like hypoxic-ischemic encephalopathy and bronchopulmonary dysplasia. Further research in preclinical neonate models could lead to clinical trials for high-risk infants.
Area of Science:
- Neonatal medicine
- Regenerative medicine
- Pediatric oncology
Background:
- Stem cells are standard in pediatric oncology and for infant immunodeficiencies.
- Severe neonatal conditions like hypoxic-ischemic encephalopathy and bronchopulmonary dysplasia affect high-risk infants.
- Preclinical models for these neonatal diseases have been established.
Purpose of the Study:
- To evaluate the potential of stem cell administration for improving clinical outcomes in high-risk infants.
- To explore regenerative therapies for severe neonatal diseases.
- To determine the significance of autologous stem cell administration in neonates.
Main Methods:
- Utilizing established animal models for neonatal diseases.
- Analyzing preclinical results of stem cell administration.
- Planning for carefully controlled clinical trials.
Main Results:
- Preclinical data suggest stem cell administration is a promising therapeutic tool.
- Stem cell therapy may improve clinical outcomes in high-risk infants.
- Further evaluation in preclinical neonate models is warranted.
Conclusions:
- Regenerative therapies, including stem cells, hold potential for treating severe neonatal conditions.
- Controlled clinical trials are indicated to assess the benefits of autologous stem cell administration.
- Stem cell therapy could significantly improve the prognosis for high-risk neonates.
Abstract:
Regenerative therapy based on stem cells is applied as standard therapy in pediatric oncology. Furthermore, they are frequently used to treat immunodeficiency disorders of infants. For severe neonatal diseases, e. g. hypoxic-ischemic encephalopathy in term neonates or bronchopulmonary dysplasia in preterm infants, animal models have been established. According to some first preclinical results stem cell administration appears as a promising tool to improve the clinical outcome in high-risk infants. Provided the benefit of regenerative therapies can further be evaluated in appropriate preclinical neonate models, carefully controlled clinical trials to assess the significance of regenerative therapies, such as autologous stem cell administration, are indicated.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Clinical Applications of Epidermal Stem Cells
Whole Body Regeneration
Neurogenesis and Regeneration of Nervous Tissue
Overview of Regeneration and Repair
Regeneration
All animals have varying degrees of...

